1. Chelidonine (Stylophorin) isolated from Chelidonium majus efficiently induced apoptosis in HeLa cells through possible alteration of p38-p53 and AKT/PI3 kinase signalling pathways. 2. Chelidonine is a promising model compound for overcoming MDR and for enhancing cytotoxicity of chemotherapeutics, especially against leukaemia cells, its efficacy needs to be confirmed in animal models. 3. Chelidonine may be a potential therapeutic agent against metastasis of invasive human cancer cells, exhibits antimigratory and antiinvasive effects in MDA-MB-231 cells, by suppressing COL-induced integrin signaling, through inhibiting the formation of the IPP complex and subsequent downregulation of IPP downstream signaling molecules, such as Akt and ERK1/2.

Chelerythrine Chloride is a cell-permeable inhibitor of protein kinase C, competitive with respect to the phosphate acceptor and non-competitive with respect to ATP.

Dihydrosanguinarine is a natural compound isolated from the leaves of Macleaya microcarpa,and has antifungal and anticancer activity.

1. Chelerythrine (Broussonpapyrine) may have antimanic effect . 2. Chelerythrine can inhibit telomerase activity. 3. Chelerythrine is a well-known protein kinase C inhibitor . 4. Chelerythrine has potential antiproliferative and antitumor effects.

Ethoxysanguinarine (6-Ethoxydihydrosanguinarine) shows human blood acetylcholinesterase (HuAChE) and human plasma butyrylcholinesterase (HuBuChE) inhibitory activity, with IC50 values of 0.83 +/- 0.04 microM and 4.20 +/- 0.19 microM, respectively.

Norchelerythrine shows significant inhibitory activity against Staphylococcus aureus ATCC 6538 with MIC values ranging from 12.5 to 50 ug/mL. It exhibits strong antifeeding activity in a concentration-dependant manner with the EC50 of 62.67 ppm.

Norsanguinarine has antifungal activity, it exhibits 100 % inhibition of A. brassicicola and C. maculans at 1000 ppm whereas. It shows significant cytotoxic activities (ED (50) values < 4 microg/ml) against P-388, KB16, A549, and HT-29 cell lines.

Chelidimerine is a natural product for research related to life sciences. The catalog number is TN3631 and the CAS number is 39110-99-1.

8-Acetonyldihydrosanguinarine is a natural product

6-Ethoxychelerythrine (Ethoxychelerythrin) has anti-bacterial activity, it exhibited strong activity against Aspergillus fumigatus and methicillin-resistant Staphylococcus aureus (MRSA).

Oxychelerythrine shows high modulatory activity enhancing the susceptibility of the S. aureus ATCC 6538 to all the tested antibiotics from two to four-fold. It also shows antifeeding activities against Tribolium castaneum adults, with the EC50 of 192.32 p

Chelidonic acid (Jervaic acid) is a component of Chelidonium majus L., used as a mild analgesic, an antimicrobial, an acentral nervous system sedative. Chelidonic acid (Jervaic acid) also shows anti-inflammatory activity.

1. Dihydrochelerythrine (12,13-Dihydrochelerythrine) is nontoxic up to 5μM concentration. 2. Dihydrochelerythrine has antifungal activity against pathogenic plant fungi. 3. Dihydrochelerythrine has potential application in the therapy of serious infection caused by I. multifiliis. 4. Dihydrochelerythrine affects cell cycle distribution, activates mitochondrial apoptotic pathway, and induces apoptosis and necrosis in HL-6 cells.

Cycleanine has potent antibacterial, antifungal, antiplasmodial, and cytotoxic activities.

1. Coptisine chloride (NSC-119754) can be absorbed across intestinal epithelial cells, and completely absorbed compounds.

Stylopine is a protoberberine-type alkaloid that has potential biological activities, including anti-inflammatory activity.

1. Coptisine sulfate has growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program.

1. Coptisine (Coptisin) treatment increases cell viability based on its reversal effect on the enhanced activity of Indoleamine 2, 3-dioxygenase . 2. Coptisine treats myocardial I/R likely through suppressing myocardial apoptosis and inflammation by inhibiting the Rho/ROCK pathway. 3. Coptisine is a potential anti-osteosarcoma drug candidate, via exerting a strong anti-osteosarcoma effect with very low toxicity . 4. Coptisine with a high dosage could inhibit cholesterol synthesis via suppressing the HMGCR expression and promoting the use and excretion of cholesterol via up-regulating LDLR and CYP7A1 expression. 5. Coptisine suppresses adhesion, migration and invasion of MDA-MB-231 breast cancer cells in vitro, the down-regulation of MMP-9 in combination with the increase of TIMP-1 possibly contributing to the anti-metastatic function for breast cancer.